Annual Drug Patent Expirations for IBRANCE
Ibrance is a drug marketed by Pfizer and is included in two NDAs. It is available from two suppliers. There are six patents protecting this drug and one Paragraph IV challenge.
Drug patent litigation for IBRANCE.
This drug has one hundred and forty-eight patent family members in fifty-six countries.
The generic ingredient in IBRANCE is palbociclib. Two suppliers are listed for this compound. Additional details are available on the palbociclib profile page.
For more information on how DrugPatentWatch can help with your pharmaceutical business intelligence needs, contact admin@DrugPatentWatch.com or visit www.DrugPatentWatch.com
